Thermo Fisher Scientific Inc · NYSE:TMO
Thermo Fisher Scientific — Merger or Acquisition (April 2013)
12 slides from Thermo Fisher Scientific's merger presentation, Apr 15, 2013
Slide 1: Thermo Fisher Scientific to Acquire Life Technologies
Exhibit 99.2 Thermo Fisher Scientific to Acquire Life Technologies April 15, 2013 Proprietary & Confidential The world leader in serving science
Slide 2: Safe Harbor Statement / Use of Non-GAAP Financial Measures
Safe Harbor Statement / Use of Non-GAAP Financial Measures The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements that involve a number of risks and uncertainties. Important factors that co
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It This communication may be deemed to be solicitation material in respect of the proposed acquisition of Life Technologies by Thermo Fisher. In connection with the proposed acquisition, Life Technologies intends to file relevant materials with the SEC, inclu
Slide 4: Combination Creates Unrivaled Industry Leader
Combination Creates Unrivaled Industry Leader Technology and Innovation Leader Ultimate Customer Partner Compelling Financial Profile 4
Slide 5: Life Technologies Company Profile
Life Technologies Company Profile Attractive revenue profile* Japan Instruments 10% 15% APAC 14% • A global leader in life sciences Americas • 2012 Revenue: $3.8 billion Consumables Europe 45% & Services 31% • 10,000 Employees 85% • 50,000+ Products Mix Regions Key product categories Premier life sc
Slide 6: Strategic Rationale
Strategic Rationale Strengthens Value Proposition for Our Customers Enhances scale and depth of capabilities in research, specialty diagnostics and applied markets Technology leadership in proteomics, genomics and cell biology World-class e-commerce and supply-chain infrastructure Industry-leading p
Slide 7: Unrivaled Industry Leadership
Unrivaled Industry Leadership Pro forma revenues: $16.3B* Lab Products & Services XX% ROW Services 4% Life Technologies 12% 23% Asia-Pacific Lab Products & 18% Services North 35% Instruments & Consumables America Equipment 61% 52% Analytical 27% Technologies Europe 24% 26% Specialty Diagnostics 18%
Slide 8: Technology and Innovation Leader
Technology and Innovation Leader Applied Specialty Research and Discovery Production Markets Diagnostics • Protein sample prep • Single-use • Food safety • Biomarkers • Laboratory consumables bioprocess • Environmental • Transplant • Research chemicals technologies • Microbiology • Cell factories •
Slide 9: Ultimate Customer Partner
Ultimate Customer Partner Commercial Reach Deep Applications Expertise • Global key accounts and strategic • 2,700 scientists partnerships • >8,000 patents and licenses • Unparalleled customer access • Industry’s largest R&D budget • Unmatched customer channels in research and healthcare • Leading e
Slide 10: Compelling Financial Profile
Compelling Financial Profile • Total cash consideration of $13.6 billion ($76 per fully diluted share) Price • Plus assumption of Life Technologies net debt, $2.2 billion as of year-end 2012 • Attractive return profile and strong cash flow • Adjusted ROIC* to exceed cost of capital in year 4 Returns
Slide 11: Transaction Overview
Transaction Overview • Fully committed bridge facility in place • Permanent financing from available cash, and issuance Financing of new debt and equity prior to close • Expected mix: $9.5 - $10 billion of cash and debt and up to $4 billion of equity financing • Pro forma leverage ratio of 4.3 - 4.4
Slide 12: Combination Creates Unrivaled Industry Leader
Combination Creates Unrivaled Industry Leader Technology and Innovation Leader Ultimate Customer Partner Compelling Financial Profile 12
Thermo Fisher Scientific — Merger or Acquisition (April 2013) on 6ix